INTRODUCTION: Newly diagnosed indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) patients are often monitored for disease progression to delay the impact of cancer-directed therapy on patients' quality of life. However, research on quality of life in patients under active surveillance versus in cancer-directed treatment has yielded mixed results. This study examined distress and quality of life in indolent NHL/CLL patients in active surveillance or cancer-directed treatment over the first-year post-diagnosis. PATIENTS AND METHODS: Adult patients (≥21 years) with newly diagnosed indolent NHL/CLL completed electronic self-report measure of distress and quality of life every 4 months over the course of a year for a total of 4 surveys. Fisher's exact test and t-tests were used to examine demographic and disease differences between patients receiving different treatments. Mixed-effect models were also used to compare overall differences between treatment status over time, accounting for missing values. RESULTS: The sample consisted of 64 patients with known baseline treatment status who did not change treatments over the course of the study. Total quality of life and physical, social and functional quality of life improved over time in patients receiving cancer-directed treatment and decreased over time in patients under active surveillance. Relative to patients in active treatment, overall, social, and functional quality of life in patients under surveillance changed more slowly over time. DISCUSSION: Active surveillance may have negative implications for patient quality of life, despite that a common goal of active surveillance is to delay the impact of treatment (e.g., appointments, toxicities) on quality of life.
INTRODUCTION: Newly diagnosed indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) patients are often monitored for disease progression to delay the impact of cancer-directed therapy on patients' quality of life. However, research on quality of life in patients under active surveillance versus in cancer-directed treatment has yielded mixed results. This study examined distress and quality of life in indolent NHL/CLL patients in active surveillance or cancer-directed treatment over the first-year post-diagnosis. PATIENTS AND METHODS: Adult patients (≥21 years) with newly diagnosed indolent NHL/CLL completed electronic self-report measure of distress and quality of life every 4 months over the course of a year for a total of 4 surveys. Fisher's exact test and t-tests were used to examine demographic and disease differences between patients receiving different treatments. Mixed-effect models were also used to compare overall differences between treatment status over time, accounting for missing values. RESULTS: The sample consisted of 64 patients with known baseline treatment status who did not change treatments over the course of the study. Total quality of life and physical, social and functional quality of life improved over time in patients receiving cancer-directed treatment and decreased over time in patients under active surveillance. Relative to patients in active treatment, overall, social, and functional quality of life in patients under surveillance changed more slowly over time. DISCUSSION: Active surveillance may have negative implications for patient quality of life, despite that a common goal of active surveillance is to delay the impact of treatment (e.g., appointments, toxicities) on quality of life.
Authors: Nadine Kutsch; Raymonde Busch; Jasmin Bahlo; Jiri Mayer; Manfred Hensel; Georg Hopfinger; Georg Hess; Ulrich von Grünhagen; Clemens-Martin Wendtner; Anna Maria Fink; Kirsten Fischer; Michael Hallek; Barbara Eichhorst Journal: Leuk Lymphoma Date: 2016-06-29
Authors: Lynne I Wagner; Fengmin Zhao; Fangxin Hong; Michael E Williams; Randy D Gascoyne; John C Krauss; Ranjana H Advani; Ronald S Go; Thomas M Habermann; Joseph W Leach; Brian O'Connor; Stephen J Schuster; David Cella; Sandra J Horning; Brad S Kahl Journal: J Clin Oncol Date: 2015-01-20 Impact factor: 44.544
Authors: Tait D Shanafelt; Deborah Bowen; Chaya Venkat; Susan L Slager; Clive S Zent; Neil E Kay; Megan Reinalda; Jeff A Sloan; Timothy G Call Journal: Br J Haematol Date: 2007-10 Impact factor: 6.998
Authors: Bryce B Reeve; Arnold L Potosky; Ashley Wilder Smith; Paul K Han; Ron D Hays; William W Davis; Neeraj K Arora; Samuel C Haffer; Steven B Clauser Journal: J Natl Cancer Inst Date: 2009-06-09 Impact factor: 13.506
Authors: Kathleen J Yost; Carrie A Thompson; David T Eton; Cristine Allmer; Shawna L Ehlers; Thomas M Habermann; Tait D Shanafelt; Matthew J Maurer; Susan L Slager; Brian K Link; James R Cerhan Journal: Leuk Lymphoma Date: 2012-09-06